Collegium Pharmaceutical, Inc.
400 Highland Corporate Drive
Cumberland
Rhode Island
02864
United States
Tel: 401-762-2000
Fax: 401-762-2043
Website: http://www.collegiumpharma.com/
196 articles about Collegium Pharmaceutical, Inc.
-
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
2/22/2024
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter and full-year ended December 31, 2023, and provided a corporate update.
-
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
2/8/2024
Collegium Pharmaceutical, Inc. today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024.
-
Collegium Provides 2024 Financial Guidance
1/3/2024
Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company, announced its 2024 full-year financial guidance and provided a business update.
-
Collegium to Participate in Upcoming November 2023 Investor Conferences
11/8/2023
Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, announced that management will participate in the following investor conferences.
-
Collegium Reports Third Quarter 2023 Financial Results
11/7/2023
Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, reported its financial results for the quarter ended September 30, 2023, and provided a corporate update.
-
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
10/24/2023
Collegium Pharmaceutical, Inc. announced that it will report third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023.
-
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
8/28/2023
Collegium Pharmaceutical, Inc. announced that 10 poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2023, being held in Las Vegas, NV from September 5–8, 2023.
-
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
8/24/2023
Collegium Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted New Patient Population exclusivity for Nucynta®, an immediate release formulation of tapentadol.
-
Collegium Announces $50 Million Accelerated Share Repurchase Program
8/7/2023
Collegium Pharmaceutical, Inc. today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock.
-
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
8/3/2023
Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, reported its financial results for the quarter ended June 30, 2023, and provided a corporate update.
-
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
7/20/2023
Collegium Pharmaceutical, Inc. today announced that it will report second quarter 2023 financial results after the market closes on Thursday, August 3, 2023.
-
Collegium to Participate in Jefferies 2023 Healthcare Conference
6/1/2023
Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, announced that management will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023.
-
Collegium Reports First Quarter 2023 Financial Results
5/4/2023
Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, reported its financial results for the quarter ended March 31, 2023, and provided a corporate update.
-
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
4/20/2023
Collegium Pharmaceutical, Inc. announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023.
-
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
4/11/2023
Collegium Pharmaceutical, Inc. announced that management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17-20, 2023.
-
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
2/23/2023
Collegium Pharmaceutical, Inc. today reported its financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.
-
Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
2/22/2023
Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company, announced the release of its inaugural Environmental, Social and Governance report.
-
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
2/8/2023
Collegium Pharmaceutical, Inc. announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering - February 06, 2023
2/6/2023
Collegium Pharmaceutical, Inc. announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
2/6/2023
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2022.